- 1 Myosin and the Actin skeleton
- 2 Tropomyosin Isoforms and Evolution
- 3 Genes and Isoforms (Isoform Complexity)
- 4 Splicing
- 5 Evolution of Isoform Generation
- 6 Spatial sorting of tropomyosin isoforms
- 7 Isoforms are not functionally redundant
- 8 Specific Roles and Functions
- 9 Role in Diseases
- 10 Tools and Technologies to study Tropomyosins
- 11 References
- 12 External links
All organisms contain structures that provide physical integrity to their cells. These structures are collectively known as the cytoskeleton, and one of the most ancient systems is based on filamentous polymers of the protein actin. A second polymer of the protein, tropomyosin, is an integral part of most actin filaments in animals.
Tropomyosins are a large family of integral components of actin filaments that play a critical role in regulating the function of actin filaments in both muscle and nonmuscle cells. These proteins consist of rod-shaped coiled-coil hetero- or homo-dimers that lie along the α-helical groove of most actin filaments. Interaction occurs along the length of the actin filament, with dimers aligning in a head-to-tail fashion.
Tropomyosins are often categorised into two groups, muscle tropomyosin isoforms and nonmuscle tropomyosin isoforms. Muscle tropomyosin isoforms are involved in regulating interactions between actin and myosin in the muscle sarcomere and play a pivotal role in regulated muscle contraction. Nonmuscle tropomyosin isoforms function in all cells, both muscle and nonmuscle cells, and are involved in a range of cellular pathways that control and regulate the cell’s cytoskeleton and other key cellular functions.
The actin filament system that is involved in regulating these cellular pathways is more complex than the actin filament systems that regulates muscle contraction. The contractile system relies upon 4 actin filament isoforms and 5 tropomyosin isoforms1 , whereas the actin filament system of the cytoskeleton uses 2 actin filament isoforms and over 40 tropomyosin isoforms.12
In direct contrast of the ‘one gene, one polypeptide’ rule, we now know from a combination of genomic sequencing, such as the Human Genome Project and EST data of expressed proteins that many eukaryotes produce a range of proteins from a single gene. This plays a crucial role in the functionality of higher eukaryotes, with humans expressing more than 5 times as many different proteins (isoforms) through alternative splicing than they have genes. From a mechanistic point of view, it is much easier for an organism to expand on a current gene/protein family (creating protein isoforms) than it is to create an entirely new gene. From an evolutionary point of view, tropomyosins in higher eukaryotes are notable in retaining all 4 of the potential genes produced by the dual genomic duplication event that took place in early eukaryotic evolution.
Within mammals, four genes are responsible for generating more than 40 different tropomyosin isoforms. In terms of structure, the genes are very similar, suggesting that they arose through gene duplication of an ancestral gene. In humans, these genes are no longer linked and are widely dispersed. In humans, the α-, β-, γ-, and δ-genes are formally known as TPM1, TPM2, TPM3, and TPM4 and are located at 15q22,3 9p13,4 1q225 and 19p13,6 respectively.
Isoforms are defined as highly related gene products that perform, in essence, similar biological functions, with variations existing between the isoforms in terms of biological activity, regulatory properties, temporal and spatial expression, and/or the intercellular location. Isoforms are produced by two distinct mechanisms, gene duplication and alternative splicing. The former mechanism is a process by which multiple copies of a gene are generated through unequal crossing over, through tandem duplication, or by translocation. Alternative splicing is a mechanism wherein exons are either retained in the mRNA or targeted for removal in different combinations to create a diverse array of mRNAs from a single pre-mRNA
A vast array of tropomyosin isoforms are generated by using a combination of different genes and alternative splicing.7 In mammals, regardless of the gene, transcription is initiated at the start of either exon 1a or exon 1b. Depending on which promoter and initial exon used, the tropomyosin isoforms can be categorized as either high-molecular-weight (HMW, 284 amino acids) or low-molecular-weight (LMW, 248).18 HMW isoforms express exon 1a and either 2a or 2b, while LMW isoforms express exon 1b.8 To date, all known tropomyosins contain exons 3-9. Alternative splicing can occur at exon 6, with the mutually exclusive choice of exon 6a or 6b.9 At the c-terminus, the transcript is spliced again at exon 9, with the choice of exon 9a, 9b, 9c, or 9d.9
In terms of structure, the genes are very similar, suggesting that they arose through gene duplication of an ancestral gene. The most highly related genes are the α- and γ-genes, utilizing two promoters and differing only with the presence of the unique 2a exon in the α-gene.1011 Although substantial differences between alternative exons from the same gene have been revealed by sequence comparison (1a and 1b, 6a and 6b, and the exon 9s), most exons are, however, highly conserved between the different genes.171213 For example, exon 1a and 1b from the α-gene vary considerably in sequence, however the sequence from exon 1a from the α-, β-, γ-, and δ-genes is highly conserved.
Due to the conservative nature of the genes, it is believed that the genes evolved from a common ancestral gene, giving rise to over 40 functionally distinct isoforms. The expression of these isoforms is highly regulated and variable throughout development. The diversity of tropomyosin expression, both in space and in time, provides the potential not only to regulate actin filament function but to create specialised actin filament populations.
Numerous reports detail that tropomyosin isoforms are sorted to different intracellular locations, often associating with actin filament populations that are involved in specific processes.14151617 Direct visualization of spatial segregation of isoforms was initially observed by Burgoyne and Norman and soon after by Lin and co-workers.171819 They observed that specific isoforms were associated with distinct cellular structures.17 Using specific antibodies, they were able to identify the presence of both HMW and the LMW isoforms of the γ-gene in stress fibers, however only LMW isoforms were detected in ruffling membranes.17
These studies have been extended to a number of cell types with similar results. Extensive studies in neuronal cells,20 fibroblasts,151621 skeletal muscle2223 and osteoclast cells has further highlighted the complex association tropomyosin isoforms have with cellular structures. These studies have led to the realization that the regulation of isoform sorting is extremely complex and highly regulated.
Sorting of tropomyosin isoforms in discrete intracellular locations is developmentally regulated. Initial studies reported that the sorting of isoforms changed through development, where Tropomyosin 4 was initially localized to the growth cone of growing neurons, but in mature neurons it was relocated to the somatodendritic compartment.24 These observations have been supported by studies on different tropomyosin isoforms, showing how tropomyosin populations were relocated during neuron maturation. This evidence is supportive of the notion that tropomyosin isoforms are subject to temporal regulation.
Additional studies have identified the role the cell cycle plays in isoform sorting. A study that screened a range HMW products from the α- and β-genes and compared localisation with LMW products from the γ-gene found that the HMW and LMW products are mutually exclusively segregated during the early G1 phase of the cell cycle.16
While studies suggest that tropomyosin sorting may be influenced by the sorting of mRNAs,20 there is no absolute correlation between mRNA and protein location. In neurons, Tropomyosin 5NM1 mRNA was found to sort to the pole of the neuron elaborating an axon prior to morphological differentiation.25 The sorting of Tropomyosin 5NM1/2 mRNA to this location correlated with the expression of the Tropomyosin 5NM1/2 protein. In contrast, the mRNA encoding the Tropomyosin Br2 protein was excluded from the pole of the neuron.25
The link between mRNA sorting and protein location has been tested in transgenic mice models. The models were created so that the coding regions of Tropomyosin 5NM1/2 and Tropomyosin 3 were expressed under the control of the β-actin promoter with the a β-actin 3’-untranslated region lacking targeting information.26 The study found that Tropomyosin 3, an isoform that is not normally expressed in neuronal cells, was broadly distributed throughout the neuron, while exogenous expression of the neuronal isoform Tropomyosin 5NM1/2 was found to sort to the growth cone of neurons as does the endogenous Tropomyosin 5NM1/2. As these two transgenes differ only in the tropomyosin coding region yet are localized in two distinct areas, the findings suggest that, in addition to mRNA sorting, the proteins themselves contain sorting information.
Studies suggest that tropomyosin isoform sorting may also be influenced by the actin isoform composition of microfilaments.26 In myoblasts, overexpression of γ-actin resulted in the down-regulation of β–actin and the removal of Tropomyosin 2 but not Tropomyosin 5 from stress fibers.27 It was later found that, when cells were exposed to cytochalasin D, a chemical that results in the disorganization of actin filaments, tropomyosin isoform sorting was disrupted. Upon the washing out of cytochalasin D, tropomyosin isoform sorting was re-established.28 This is suggestive of a strong relationship between the process of tropomyosin isoform sorting and the incorporation of tropomyosin isoforms into organized arrays of actin filaments. There is no evidence for active transport of tropomyosin isoforms to specific locations. Rather, it appears that sorting is the result of local assembly of preferred isoforms at specific intracellular site. The mechanisms that underlie tropomyosin isoform sorting appear to be inherently flexible and dynamic in nature.
Many studies have led to the understanding that tropomyosins perform essential functions and are required in a diverse range of species from yeast, worms, and flies to complex mammals.
The essential role of tropomyosins was discovered in the Bretscher laboratory, where researchers found that, by eliminating the TPM1 gene of budding yeasts, growth rates were reduced, the presence of actin cables disappeared, defects in vesicular transport were observed, and mating of the yeast was poor.29 When a second yeast gene, TPM2, was deleted, no observable changes in the phenotype were recorded; however, when deleted in combination with TPM1, it resulted in lethality. This suggests that TPM1 and -2 genes have overlapping function, however TPM2 cannot fully compensate of the loss of TPM1, indicating that some functions of TPM1 are unique. Similar results have been observed in flies, worms, amphibians, and mammals, confirming previous results and suggestive of tropomyosin's being involved in a wide range of cellular functions. However, the three co-expressed TMP1, 2, and 4 genes cannot compensate for deletion of the TPM3 gene in embryonic stem cells and preimplantation mouse embryos.
Results from gene knockout experiments can be ambiguous and must be carefully examined. In studies in which the deletion of a gene leads to lethality, it can at first appear that the gene product had a truly unique role. However, lethality can also be the result of the inability of the compromised cell to express other isoforms to rescue the phenotype because the required isoform is not naturally expressed in the cell.
The actin microfilment system is the fundamental cytoskeletal system involved in the development and maintenance of cell morphology. The ability of this system to readily respond to cellular cues and undergo structural re-organisation has led to the belief that this system regulates specific structural changes within different cellular regions.
Within humans, there are only six actin isoforms, and these isoforms are responsible for an array of unique and complex cellular structures and key cellular interactions. It is thought that the function and form of the actin cytoskeleton is controlled largely by actin-binding proteins (ABP) that are associated with the actin polymer. ABP are a group of proteins that bind to actin. Although tropomyosin is sometimes included as an ABP, it is not a true ABP. The tropomyosin dimer has very low affinity for an actin filament and forms no van der waals contacts with actin. It is only the formation of a tropomyosin polymer's winding around the actin filament that provides stability to the tropomyosin-actin filament interaction.
Many studies suggest that the binding of tropomyosin isoforms to an actin filament may influence the binding of other ABPs, which together alter the structure and convey specific properties and ultimately specific functions to an actin filament. This is demonstrated in neuroepithelial cells, where increased expression of Tropomyosin 5NM1 increases the recruitment of myosin IIB, a myosin motor protein to the growth cone area.30 However, the over-expression of Tropomyosin Br3 had the opposite effect, decreasing myosin activity in the same region.
In a pioneering study by Bernstein and Bamburg, it was observed that the actin-binding protein actin depolymerisation factor (ADF)/cofilin, a factor that promotes actin filament depolymerisation, competed with tropomyosin for binding to the actin filament.31 The expression of Tropomyosin 5NM1 in neuronal cells eliminated ADF/cofilin from the growth cone region, leading to more stable actin filaments.30 However, the increased expression of Tropomyosin Br3 was observed to recruit ADF/cofilin to actin filaments bound to the Tropomyosin Br3 isoform within the lamellipodium, which led to the disassembly of actin filaments.30 This phenomenon, whereby a specific tropomyosin isoform directs specific interactions between actin-binding proteins, and the actin filament has been observed in a variety of model systems with a range of different binding proteins (reviewed in Gunning et al., 20089). These interactions, under the influence of tropomyosin isoforms, allow actin filaments to be involved in a diverse range of cellular functions.
Skeletal muscle is composed of large, multi-nucleated cells (muscle fibers). Each muscle fiber is packed with longitudinal arrays of myofibrils. Myofibrils are composed of repeating protein structures or sarcomeres, the basic functional unit of skeletal muscle. The sarcomere is a highly structured protein array, consisting of interdigitating thick and thin filaments, where the thin filaments are tethered to a protein structure, the Z-line. The dynamic interaction between the thick and thin filaments results in muscle contraction.
Myosin belongs to a family of motor proteins, and the muscle isoforms of this family comprise the thick filament. The thin filament is made of the skeletal muscle isoforms of actin. Each myosin protein ‘paddles’ along the thin actin filament, repeatedly binding to myosin-binding sites along the actin filament, ratcheting and letting go. In effect, the thick filament moves or slides along the thin filament, resulting in muscle contraction. This process is known as the sliding filament model.
The binding of the myosin heads to the muscle actin is a highly regulated process. The thin filament is made of actin, tropomyosin, and troponin. The contraction of skeletal muscle is triggered by nerve impulses that in turn stimulate the release of Ca2+. The release of Ca2+ from the sarcoplasmic reticulum causes an increase in the concentration of Ca2+ in the cytosol. Calcium ions then bind to troponin, which is associated with tropomyosin. Binding causes changes in the shape of troponin and subsequently causes the tropomyosin isoform to shift its position on the actin filament. This shifting in position exposes the myosin-binding sites on the actin filament, allowing the myosin heads of the thick filament to bind to the thin filament.
Structural and biochemical studies suggest that the position of tropomyosin and troponin on the thin filament regulates the interactions between the myosin heads of the thick filament and the binding sites on the actin of the thin filament. X-ray diffraction and cryoelectron microscopy suggest that tropomyosin sterically blocks the access of myosin to the actin filament.
Although this model is well-established, it is unclear as to whether the movement of tropomyosin directly causes the myosin head to engage the actin filament. As such, an alternative model has emerged, whereby the movement of the tropomyosin in the filament functions as an allosteric switch that is modulated by activating myosin binding but does not function solely by regulating myosin binding.
Smooth muscle is a type of non-striated muscle, and, unlike striated muscle, contraction of smooth muscle is not under conscious control. Smooth muscle may contract spontaneously or rhythmically and be induced by a number of physiochemical agents (hormones, drugs, neurotransmitters). Smooth muscle is found within the walls of various organs and tubes in the body such as the esophagus, stomach, intestines, bronchi, urethra, bladder, and blood vessels.
Although smooth muscles do not form regular arrays of thick and thin filaments like the sarcomeres of striated muscles, contraction is still due to the same sliding filament mechanism controlled by myosin crossbridges interacting with actin filaments. The thin filament of smooth muscle is made of actin, tropomyosin, caldesmon, and calmodulin. Within this type of muscle, caldesmon and calmodulin control the tropomyosin-mediated transition between on and off activity states. Caldesmon binds to actin, tropomyosin, calmodulin, and myosin, of which its interactions with actin are most important. The binding of caldesmon is strongly influenced by tropomyosin. Caldesmon is an inhibitor of actinomyosin ATPase and motility, and both actin binding and caldesmon inhibition are greatly enhanced in the presence of tropomyosin.
Smooth muscle contraction is initiated by the release of Ca2+. Ca2+ binds to and activates calmodulin, which then binds to caldesmon. This binding causes the caldesmon protein to disengage from the actin filament, exposing the myosin-binding sites on the actin filament. Myosin motor heads are phosphorylated by myosin light-chain kinase, allowing the myosin head to interact with the actin filament and cause contraction.
The cyctoskelton is an elaborate network of filaments required for the proper functioning of a range of cellular processes including cell motility, cell division, intracellular trafficking, and the maintenance of cell shape. The cytoskeleton is composed of three distinct filament systems: microtubules, intermediate filaments, and microfilaments (also known as the actin cytoskeleton). It is the dynamic interactions between these filaments that provide cells with unique structures and functions.
A number of regulatory mechanisms, employing many actin-binding proteins, have evolved to control the dynamics of the actin filament system. It is believed that tropomyosins play a pivotal role in this regulatory system, influencing the associations the actin filament has with other ABPs. Together, these associations confer specific properties on the filament, allowing these structures to be involved in a wide range of cellular processes, but also to rapidly respond to cellular stimuli.
Many studies have shown that there are specific changes to the repertoire of tropomyosins expressed in cells that are undergoing cellular transformation. These highly reproducible results suggest that, during the process of cellular transformation, a process whereby a normal cell becomes malignant, there is a decreased synthesis of HMW tropomyosin isoforms. In the initial studies, transformation of rat embryo fibroblast cell line REF-52 and of normal rat kidney cells led to decreased synthesis of HMW tropomyosins.323334 In both of these systems, the down regulation was contributed to a decrease in the mRNA levels. These early results suggested that tropomyosins played a critical role in facilitating certain processes that occurred during cell transformation, such as actin filament re-organisation and changes in cell shape. These studies have been reproduced in other laboratories and in other cell lines, with similar results (reviewed in Gunning et al., 20089).
Furthermore, studies have highlighted a link between tropomyosin isoform expression and the acquisition of metastatic properties. A study compared isoform expression between a low- and highly-metastatic Lewis lung carcinoma cell line.3536 It is interesting to note that the study found that, as cells become more metastatic, there is a marked decrease in the expression of HMW tropomyosin 2 protein and mRNA levels.
These results have been confirmed in primary tumors and human models. Studies in colon and bladder cancer found increased expression of the LMW tropomyosin Tropomyosin 5NM1.3738 The elevated expression of this isoform has also been seen in transformed rat fibroblasts, and it is thought that this isoform is required for the motility of highly metastatic melanoma.39 In addition, elevated expression of Tropomyosin 4 has been linked with lymph node metastasis in breast cancer.
All of these studies suggest that changes in the expression and complement of tropomyosin isoforms are integral to cancer and cancer progression. The consensus is that, in general, cancer cells become more reliant on LMW tropomyosins as HMW tropomyosins disappear with increasing malignancy.9 This discovery has led to the development of novel anti-tropomyosin compounds as potential anti-cancer agents.
Tropomyosins have been implicated in the autoimmune disease ulcerative colitis, a disease of the colon that is characterised by ulcers or open sores. The link between this disease and tropomyosin was first acknowledged in a study that found blood serum taken from 95% of patients with ulcerative colitis contained antibodies that reacted positively to tropomyosin.40 Additional studies have confirmed these results, but also identify Tropomyosin 5 and Tropomyosin 1 as the primary tropomyosins involved in the pathogenesis of ulcerative colitis.4142 Tropomyosin 5 has been related to the development of pouchitis in the ileal pouch following surgery for ulcerative colitis. The elevated number of IgG-producing cells in the colonic mucosa of ulcerative colitis patients is largely committed to producing IgG against Tropomyosin 5-related epitopes. Tropomyosin 5 is, therefore, capable of inducing a significant T-cell response.43 A physicochemical analysis of common structural motifs present in 109 human autoantigens revealed that tropomyosins have the highest number of such motifs, and thus a very high propensity to act as autoantigens.44
In addition to the role tropomyosins play in ulcerative colitis, tropomyosin antibodies have also been reported in acute rheumatic fever 45 and the inflammatory disorder, Behcet’s syndrome.46 In both instances, it is unclear as to whether these antibodies play a direct role in the pathogenesis of these human conditions or reflect the high antigenicity of tropomyosins released from compromised cells.
Nemaline myopathy is a muscle disease that is characterised by the presence of electron-dense rod bodies in skeletal muscle fibers. These electron-dense rod bodies are composed mainly of α-actinin and actin. The disorder is often clinically categorized into several groups, including mild (typical), intermediate, severe, and adult-onset; however, these distinctions are somewhat ambiguous, as the categories frequently overlap. Causative mutations have been detected in skeletal α-actinin, tropomyosin, nebulin, and troponin. Within humans, mutations in both the γ-Tropomyosin and β-Tropomyosin genes have been identified. No mutations in the α-Tropomyosin gene have been identified in this condition for humans.
Within the scientific community, there is great interest in tropomyosin isoforms, and, given the vast array of processes that this protein has been reported to be involved with, it is not surprising.
One way in which this protein and, what is more important, specific isoforms can be studied in detail is through the use of antibodies. These specific antibodies can be used in protein-blotting experiments and applied to cells or tissue sections and observed under a microscope. This allows researchers not only to determine the level or concentration of an isoform or a group of isoforms but also to identify the cellular location of a particular isoform and associations with other cellular structures or proteins.
At the present time, there are many commercially available antibodies, however many of these antibodies are sold with minimal information regarding the antigen used to raise the antibody and, therefore, the isoform specificity, as such some research groups develop their own antibodies. Before these antibodies can be used, they must be extensively characterised, a process whereby the specificity of the antibody is examined to ensure that the antibody does not cross-react with other tropomyosins or other proteins.
- Pittenger, MF; Kazzaz, JA; Helfman, DM (1994). "Functional properties of non-muscle tropomyosin". Curr Opin Cell Biol 6 (1): 96–104. doi:10.1016/0955-0674(94)90122-8. PMID 8167032.
- Gunning, PW; Schevzov, G; Kee, AJ; Hardeman, EC (2005). "Tropomyosin isoforms:divining rods for actin cytoskeleton function". Trends Cell Biol 15 (6): 333–341. doi:10.1016/j.tcb.2005.04.007. PMID 15953552.
- Eyre, H; Akkari, PA; Wilton, SD; Callen, DC; Baker, E; Laing, NG (1995). "Assignment of the human skeletal muscle alpha-tropomyosin gene (TPM1) to band 15q22 by fluorescence in situ hybridization". Cytogenet Cell Genet 69 (1–2): 15–17. doi:10.1159/000133928. PMID 7835079.
- Hunt, CC; Eyre, HJ; Akkari, PA; Meredith, C; Dorosz, SM; Wilton, SD; Callen, DF; Laing, NG; Baker, E (1995). "Assignment of the human skeletal muscle beta-tropomyosin gene (TPM2) to band 9p13 by fluorescence in situ hybridization". Cytogenet Cell Genet 71 (1): 94–95. doi:10.1159/000134070. PMID 7606936.
- Wilton, SD; Eyre, H; Akkari, PA; Watkins, HC; MacRae, C; Laing, NG; Callen, DC (1995). "Assignment of the human skeletal muscle α-tropomyosin gene (TPM3) to 1q22 --> q23 by fluorescence in situ hybridization". Cytogenet Cell Genet 68 (1–2): 122–124. doi:10.1159/000133905. PMID 7956350.
- Wilton, SD; Lim, L; Dorosz, SD; Gunn, HC; Eyre, HJ; Callen, DF; Laing, NG (1996). "Assignment of the human skeletal muscle alpha-tropomyosin gene (TPM4) to band 19p13.1 by fluorescence in situ hybridization". Cytogenet Cell Genet 72 (4): 294–296. doi:10.1159/000134206. PMID 8641132.
- Lees-Miller, JP; Helfman, DM (1991). "The molecular basis for tropomyosin isoform diversity". BioEssays 13 (9): 429–437. doi:10.1002/bies.950130902. PMID 1796905.
- Martin, C; Schevzov, G; Gunning, P (2009). "Alternatively spliced N-terminal exons in tropomyosin isoforms do not act as autonomous targeting signals". J Struc Biol 170 (2): 286–293. doi:10.1016/j.jsb.2009.12.016.
- Gunning, P; O'neill, G; Hardeman, E (2008). "Tropomyosin-based regulation of the actin cytoskeleton in time and space". Physiol Rev 88 (1): 1–35. doi:10.1152/physrev.00001.2007. PMID 18195081.
- Ruiz-Opazo, N; Weinberger, J; Nadal-Ginard, B (1985). "Comparison of alpha-tropomyosin sequences from smooth and striated muscle". Nature 315 (6014): 67–70. doi:10.1038/315067a0. PMID 3838802.
- Ruiz-Opazo, N; Nadal-Ginard, B (1987). "Alpha-tropomyosin gene organization. Alternative splicing of duplicated isotype-specific exons accounts for the production of smooth and striated muscle iosforms". J Biol Chem 262 (10): 4755–4765. PMID 3558368.
- Beisel, G; Kennedy, JE (1994). "Identification of novel alternatively spliced isoforms of the tropomyosin-encoding gene, TMnm, in the rat cochlea". Gene 143 (2): 251–256. doi:10.1016/0378-1119(94)90105-8. PMID 8206382.
- Lees-Miller, JP; Goodwin, LO; Helfman, DM (1990). "Three novel brain tropomyosin isoforms are expressed from the rat alpha-tropomyosin gene through the use of alternative promoters and alternative RNA processing". Mol Cell Biol 10 (4): 1729–1742. doi:10.1128/MCB.10.4.1729 (inactive 2014-03-23). PMC 362279. PMID 2320008.
- Heimann, K; Percival, JM; Weinberger, R; Gunning, P; Stow, JL (1999). "Specific isoforms of actin-binding proteins on distinct populations of Golgi-derived vesicles". J Biol Chem 274 (16): 10743–10750. doi:10.1074/jbc.274.16.10743. PMID 10196146.
- Percival, JM; Hughes, JA; Brown, DL; Schevzov, G; Heimann, K; Vrhovski, B; Bryce, N; Stow, JL; Gunning, P (2004). "Targeting of a tropomyosin isoform to short microfilaments associated with the golgi complex". Mol Biol Cell 15 (1): 268–280. doi:10.1091/mbc.E03-03-0176. PMC 307546. PMID 14528022.
- Percival, JM; Thomas, G; Cock, TA; Gardiner, EM; Jeffrey, PL; Lin, JJ; Weinberger, RP; Gunning, P (2000). "Sorting of tropomyosin isoforms in synchronised NIH 3T3 fibroblasts: evidence for distinct microfilament populations". Cell motil Cytoskeleton 47 (3): 189–208. doi:10.1002/1097-0169(200011) (inactive 2014-03-23). PMID 11056521.
- Lin, JJ; Hegmann, TE; Lin, JL (1988). "Differential localization of tropomyosin isoforms in cultured nonmuscle cells". J Cell Biol 107 (2): 563–572. doi:10.1083/jcb.107.2.563. PMC 2115218. PMID 3047141.
- Burgoyne, RD; Norman, KM (1985). "Immunocytochemical localization of tropomyosin in rat cerebellum". Brain Res 361 (1–2): 178–184. doi:10.1016/0006-8993(85)91287-9. PMID 4084791.
- Burgoyne, RD; Norman, KM (1985). "Presence of tropomyosin in adrenal chromaffin cells and its association with chromaffin granule membranes". FEBS Lett 179 (1): 25–28. doi:10.1016/0014-5793(85)80183-6. PMID 3880708.
- Gunning, P; Hardeman, E; Jeffrey, P; Weinberger, R (1998). "Creating intracellular structural domains: spatial segregation of actin and tropomyosin isoforms in neurons". BioEssays 20 (11): 892–900. doi:10.1002/(SICI)1521-1878(199811) (inactive 2014-03-23). PMID 9872055.
- Schevzov, G; Vrhovski, B; Bryce, NS; Elmir, S; Qiu, MR; O'neill, GM; Yang, N; Verrills, NM et al. (2005). "Tissue-specific tropomyosin isoform composition". J Histochem Cytochem 53 (5): 557–570. doi:10.1369/jhc.4A6505.2005. PMID 15872049.
- Lin, JJ; Lin, JL (1986). "Creating Assembly of different isoforms of actin and tropomyosin into the skeletal tropomyosin-enriched microfilaments during differentiation of muscle cells in vitro". J Cell Biol 103 (6): 2173–2182. doi:10.1083/jcb.103.6.2173.
- Kee, AJ; Schevzov, G; Nair-Shalliker, V; Robinson, CS; Vrhovski, B; Ghoddusi, M; Qui, MR; Lin, JJ et al. (2004). "Sorting of a nonmuscle tropomyosin to a novel cytoskeletal compartment in skeletal muscle results in muscular dystrophy". J Cell Biol 166 (5): 685–696. doi:10.1083/jcb.200406181. PMC 2172434. PMID 15337777.
- Had, L; Faivre-Sarrailh, C; Legrand, C; Mery, J; Brugidou, J; Rabie, A (2005). "Tropomyosin isoforms in rat neurons:the different developmental profiles amd distributions of TM-4 and TMBr-3 are consistent with different functions". J Cell Sci 107: 2961–2973. PMID 7876361.
- Hannan, AJ; Gunning, P; Jeffrey, PL; Weinberger, RP; Weinberger, RP (1995). "Intracellular localization of tropomyosin mRNA and protein is associated with development of neuronal polarity". Mol Cell Neurosci 6 (5): 397–412. doi:10.1006/mcne.1995.1030. PMID 8581312.
- Schevzov, G; Bryce, NS; Almonte-Baldonado, R; Joya, J; Lin, JJ; Hardeman, E; Weinberger, R; Gunning, P (2005). "Specific features of neuronal size and shape are regulated by tropomyosin isoforms". Mol Biol Cell 16 (7): 3425–3437. doi:10.1091/mbc.E04-10-0951. PMC 1165423. PMID 15888546.
- Schevzov, G; Lloyd, C; Hailstones, D; Gunning, P (1993). "Differential regulation of tropomyosin isoform organization and gene expression in response to altered actin gene expression". J Cell Biol 121 (4): 811–821. doi:10.1083/jcb.121.4.811. PMC 2119789. PMID 8491774.
- Schevzov, G; Gunning, P; Jeffrey, PL; Temm-Grove, C; Helfman, DM; Lin, JJ; Weinberger, RP (1997). "Tropomyosin localization reveals distinct populations of microfilaments in neurites and growth cones". Mol Cell Neurosci 8 (6): 439–454. doi:10.1006/mcne.1997.0599. PMID 9143561.
- Lui, H; Bretscher, A (1992). "Characterization of TPM1 disrupted yeast cells indicates an involvement of tropomyosin in directed vesicular transport". J Cell Biol 118 (2): 285–299. doi:10.1083/jcb.118.2.285. PMC 2290051. PMID 1629236.
- Bryce, NS; Schevzov, G; Ferguson, V; Percival, JM; Lin, JJ; Matsumura, F; Bamburg, JR; Jeffrey, PL et al. (2003). "Specification of actin filament function and molecular composition by tropomyosin isoform". Mol Biol Cell 14 (3): 1002–1016. doi:10.1091/mbc.E02-04-0244. PMC 151575. PMID 12631719.
- Bernstein, BW; Bamburg, JR (1982). "Tropomyosin binding to F-actin protects the F-actin from disassembly by brain actin-depolymerizing factor (ADF)". Cell Motil 2 (1): 1–8. doi:10.1002/cm.970020102. PMID 6890875.
- Hendricks, M; Weintraub, H (1981). "Tropomyosin is decreased in transformed cells". Proc Natl Acad Sci USA 78 (9): 5633–5637. doi:10.1073/pnas.78.9.5633. PMC 348810. PMID 6272310.
- Hendricks, M; Weintraub, H (1984). "Multiple tropomyosin polypeptides in chicken embryo fibroblasts: differential repression of transcription by Rous sarcoma virus transformation". Mol Cell Biol 4 (9): 1823–1833. doi:10.1128/MCB.4.9.1823 (inactive 2014-03-23). PMC 368992. PMID 6208481.
- Lin, JJ; Helfman, DM; Hughes, SH; Chou, CS (1985). "Tropomyosin isoforms in chicken embryo fibroblasts: purification, characterization, changes in Rous sarcoma virus-transformed cells". J Cell Biol 100 (3): 692–703. doi:10.1083/jcb.100.3.692. PMC 2113520. PMID 2982883.
- Takenaga, K; Nakamura, Y; Sakiyama, S (1988). "Differential expression of a tropomyosin isoform in low- and high-metastatic Lewis lung carcinoma cells". Mol Cell Biol 8 (9): 3934–3937. PMC 365453. PMID 3221870.
- Takenaga, K; Nakamura, Y; Tokunaga, K; Kageyama, H; Sakiyama, S (1988). "Isolation and characterization of a cDNA that encodes mouse fibroblast tropomyosin isoform2". Mol Cell Biol 8 (12): 5561–5565. PMC 365662. PMID 3244365.
- Lin, JL; Geng, X; Bhattacharya, SD; Yu, JR; Reiter, RS; Sastri, B; Glazier, KD; Mirza, ZK et al. (2002). "Isolation and sequencing of a novel tropomyosin isoform preferentially associated with colon cancer". Gastroenterology 123 (1): 152–162. doi:10.1053/gast.2002.34154. PMID 12105844.
- Pawlak, G; McGarvey, TW; Nguyen, TB; Tomaszewski, JE; Puthiyaveettil, R; Malkowicz, SB; Helfman, DM (2004). "Alterations in tropomyosin isoform expression in human transitional cell carcinoma of the urinary bladder". Int J Cancer 110 (3): 368–373. doi:10.1002/ijc.20151. PMID 15095301.
- Miyado, K; Kimura, M; Taniguchi, S (1996). "Decreased expression of a single tropomyosin isoform, TM5/TM30nm, results in reduction in motility of highly metastatic B16-F10 mouse melanome cells". Biochem Biophys Res Commun 226 (2): 427–435. doi:10.1006/bbrc.1996.1190.
- Das, KM; Dasgupta, A; Mandal, A; Geng, X (1993). "Autoimmunity to cytoskeletal protein tropomyosin. A clue to the pathogenetic mechanism fr ulcerative colitis". J Immunol 150 (6): 2487–2493. PMID 8450225.
- biancone, L; Monteleone, G; Marasco, R; Pallone, F (1998). "Autoimmunity to tropomyosinisoforms in ulcerative colitis (UC) patients and unaffected relatives". Clin Exp Immunol 113 (2): 198–205. doi:10.1046/j.1365-2249.1998.00610.x. PMC 1905040. PMID 9717968.
- Geng, X; Biancone, L; Dai, HH; Lin, JJ; Yoshizaki, N; Dasgupta, A; Pallone, F; Das, KM (1998). "Tropomyosin isoform in intestinal mucosa: production of autoantibodies to tropomyosin isoform in ulcerative colitis". Gastroenterology 114 (5): 912–922. doi:10.1016/S0016-5085(98)70310-5. PMID 9558279.
- Biancone, L; Palmieri, G; Lombardi, A; Colantoni, A; Tonelli, F; Das, KM; Pallone, F (2003). "tropomyosin expression in the ileal pouch: a relationship with the development of pouchitis in ulcerative colitis". Am J Gastroenterol 98 (12): 2719–2726. doi:10.1111/j.1572-0241.2003.08719.x. PMID 14687823.
- Dohlam, JG; Lupas, A; Carson, M (1993). "Long charge-rich alpha-helices in systemic autoantigens". Biochem Biophys Res Commun 195 (2): 686–696. doi:10.1006/bbrc.1993.2100. PMID 8373407.
- Khanna, AK; Nomura, Y; Fischetti, VA; Zabriskie, JB (1997). "Antibodies in the sera of acute rheumatic fever patients bind to human cardiac tropomyosin". J Autoimmunity 10: 99–106. doi:10.1006/jaut.1996.0107.
- Mor, F; Weinberger, A; Cohen, IR (2002). "Identification of alpha-tropomyosin as a target self-antigen in Behcet's syndrome". Eur J Immunol 32 (2): 356–365. doi:10.1002/1521-4141(200202)32:2<356::AID-IMMU356>3.0.CO;2-9. PMID 11807775.